Pulmonx (LUNG) Free Cash Flow Growth (3y) (2022 - 2025)

Pulmonx (LUNG) Free Cash Flow Growth (3y) (2022 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 6.28%
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 9.63%
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 22.80%
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 29.36%
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -27.72%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -0.27%
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn 77.20%
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -20.37%
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 19.32%
10 Pulmonx 54.38 Mn -15.37 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 9.50%
Jun 30, 2025 28.05%
Mar 31, 2025 4.68%
Dec 31, 2024 22.02%
Sep 30, 2024 6.44%
Jun 30, 2024 24.95%
Mar 31, 2024 -7.19%
Dec 31, 2023 -6.29%
Sep 30, 2023 -12.10%
Jun 30, 2023 0.70%
Mar 31, 2023 -10.00%
Dec 31, 2022 -35.03%